Locations:
Search IconSearch

Research

Before and after scan
August 28, 2024/Cancer/Research

Case Study: Patient with Metastatic Urothelial Carcinoma Has No Remaining Evidence of Disease

Treatment involved checkpoint inhibitor, surgery and intravesical therapy

Dr. Maciejewski
August 23, 2024/Cancer/Research

Studies Evaluate Anti-Complement Inhibitors for Treating Paroxysmal Nocturnal Hemoglobinuria

Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials

Dr. Raza
August 19, 2024/Cancer/Research

Understanding the Role of Palliative Care in AL Amyloidosis

Multi-specialty coordination essential for improving quality of life

Dr. Chirag Shah and colleague
August 12, 2024/Cancer/Research

DCISionRT Decision Score Predicts the Need of Radiation Therapy for Treating Ductal Carcinoma in Situ

Seven-gene biosignature becomes first effective means to reduce over- and under-treatment with radiation therapy

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Diffuse large B-cell lymphoma
August 1, 2024/Cancer/Research

Emerging Second- and Third-Line Treatments Improve Outcomes in Diffuse Large B-Cell Lymphoma

CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management

genomic testing
July 30, 2024/Cancer/Research

New Research Highlights Novel Risk Stratification Model for Soft Tissue and Uterine Leiomyosarcoma

Approach could help clinicians identify patients at an increased risk of progression who could benefit from more aggressive treatment

Dr. Holly Pederson
July 25, 2024/Cancer/Research

Evaluating Risk Scores for Triple-Negative Breast Cancer in Black Women (Podcast)

Polygenic risk score could help predict who will develop this aggressive breast cancer

Image showing Dr. Gupta
June 20, 2024/Cancer/Research

Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

BackPage 1 of 43Next

Advertisement

Ad